The overarching goal of the Kollmann group is to define how cell cycle regulation, environmental exposures, and clonal evolution interact to shape hematopoietic stem cell fate and contribute to hematologic malignancies. We seek to understand how these intrinsic and extrinsic factors shape therapeutic response, with particular interest in mechanisms of resistance to CDK-targeted therapies. By integrating advanced cell culture systems, patient-derived and 3D in vitro models, next-generation sequencing, proteomics, and functional genomics, we dissect disease biology across molecular and cellular scales. Our long-term goal is to identify novel biomarkers and therapeutic vulnerabilities that enable more effective, durable, and less toxic treatment strategies for patients with hematologic disorders and cancers.